At a glance
ClinicalIndex Comparison Record- ✓History of chronic kidney disease: either pre-dialysis with serum creatinine ≥150 micromol/L (≥1.7 mg/dL) in men or ≥130 micromol/L (≥1.5 mg/dL) in women, OR currently on dialysis (hemodialysis or peritoneal dialysis)
- ✓Age ≥40 years
- ✕History of myocardial infarction or coronary revascularization procedure
- ✕Functioning renal transplant or living donor-related transplant planned
- ✕Less than 2 months since acute uraemic emergency presentation
- ✕Chronic liver disease or abnormal liver function (ALT >1.5× ULN or if unavailable, AST >1.5× ULN)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial
In Brief
A Phase 4 clinical trial evaluating Simvastatin 20 mg, Ezetimibe 10mg, and 1 other intervention for Kidney Disease, Chronic. Completed, enrolled 9,438 participants across 1 site.
Detailed Summary
The chief aim of SHARP was to determine whether lowering blood LDL cholesterol with simvastatin (20mg) plus ezetimibe (10mg) daily could safely reduce the risk of coronary heart disease, non-hemorrhagic stroke and the need for revascularization procedures in patients with chronic kidney disease (CKD). It also aimed to assess whether lowering LDL cholesterol reduced the rate of loss of renal function in people with CKD who had not commenced dialysis treatment.
Study Details
Timeline
Interventions
Once daily
Once daily
Once daily